Stryker Corporation (SYK)
Compared to Estimates, Stryker (SYK) Q4 Earnings: A Look at Key Metrics
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.4 per share. This compares to earnings of $4.01 per share a year ago.
SYK's Q4 Results Likely to Reflect Procedure Growth and Capital Demand
Stryker's fourth-quarter results are expected to highlight resilient procedure volumes and strong capital demand, supported by product momentum and broad-based strength.
Here's Why Stryker (SYK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gear Up for Stryker (SYK) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker
Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers despite sector-wide derating risks. Key growth drivers include Mako's continued share gains in major joints, expansion into extremities, and under-tapped potential in ambulatory surgical centers. Management prioritizes M&A for capital allocation, targeting complementary technologies in robotics, cardiology, and urology, while organic growth opportunities like Smart Care add upside.
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
Why Stryker (SYK) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Stryker (SYK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?
Over $500 million in insider stock sales have hit three high-profile companies this month—an unsettling signal that even top executives and major stakeholders may be questioning the sustainability of recent gains.
Stryker Corporation (SYK) Analyst/Investor Day Transcript
Stryker Corporation ( SYK ) Analyst/Investor Day November 13, 2025 2:30 PM EST Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin Lobo - Chairman, CEO & President Spencer Stiles - Group President of Orthopaedics Dylan Crotty - President of Instruments Kathy Truppi J. Pierce - Group President of MedSurg & Neurotechnology Tim Lanier Viju Menon - Group President of Global Quality & Operations Debra King - VP, Chief Digital & Information Officer Jessica Mathieson Preston Wells - VP & CFO Conference Call Participants Neal Patel Robert Marcus - JPMorgan Chase & Co, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Travis Steed - BofA Securities, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Christopher Pasquale - Nephron Research LLC Joanne Wuensch - Citigroup Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Joshua Jennings - TD Cowen, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Conversation Jason Beach Vice President of Finance & Investor Relations Good afternoon.
